INT186483

Context Info Confidence 0.04 First Reported 2005 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 3 Total Number 3 Disease Relevance 2.92 Pain Relevance 0.79

MYOM2 (Homo sapiens)

Pain Link Frequency Relevance Heat cva 99 98.36 dexamethasone 385 96.04 vincristine 4 21.64 Central nervous system 2 12.08 headache 1 5.04 aspirin 9 5.00 peripheral neuropathy 6 5.00 cytokine 6 5.00 corticosteroid 4 5.00 Inflammation 3 5.00

Disease Link Frequency Relevance Heat Thrombosis Related Under Development 80 98.36 Influenza Virus Infection 181 96.08 Amyloidosis 42 94.32 Multiple Myeloma 179 93.38 Infection 31 87.36 Nicotine Addiction 4 80.32 Cancer 19 79.96 Thrombophilia 7 78.08 Pulmonary Disease 93 74.64 Disease 89 65.48

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Among these, personal history of VTD (HR-47.7; P = .006, CI-2.98–766), immobility (HR-11.78; P = .006, CI-2.02–68.8), absence of measurable M-protein (HR-12.5; P = .031, CI-1.25–100), and age at diagnosis (HR-2.99, P = .041, CI-1.05–8.56) were identified as univariable correlates of VTD in amyloidosis patients (Table 4.)

Negative_regulation (absence) of M-protein associated with amyloidosis and cva

1) Confidence 0.04 Published 2005 Journal Int Semin Surg Oncol Section Body Doc Link PMC1232862 Disease Relevance 1.55 Pain Relevance 0.41

Two compounds are available that inhibit function of the M2 protein and prevent viral uncoating following endocytosis.

Negative_regulation (inhibit) of M2 protein

2) Confidence 0.01 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2692119 Disease Relevance 1.14 Pain Relevance 0

In a phase II study of 72 patients (median age 63 years) with newly diagnosed MM, induction therapy with clarithromycin 500 mg twice -daily, lenalidomide 25 mg/day on days 1–21 of a 28-day cycle, and dexamethasone 40 mg/day once weekly was associated with an objective response of PR or better in 65 (90.3%) patients (90.3%), including a CR rate of 38.9%.87 Fifty-three patients (73.6%) achieved at least a 90% decrease in M-protein levels.

Negative_regulation (decrease) of M-protein associated with multiple myeloma and dexamethasone

3) Confidence 0.01 Published 2010 Journal Core evidence Section Body Doc Link PMC2899783 Disease Relevance 0.22 Pain Relevance 0.37

General Comments

This test has worked.